Cargando…
Prevalence and Clinical Impact of SARS‐CoV‐2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID‐19 Pandemic
INTRODUCTION: In Europe, the SARS‐CoV‐2 pandemic had its first epicenter in Italy. Despite a significant mortality rate, the severity of most cases of COVID‐19 infection ranges from asymptomatic to mildly symptomatic, and silent infection affects a still‐unknown proportion of the general population....
Autores principales: | Zambelli, Alberto, Chiudinelli, Lorenzo, Fotia, Vittoria, Negrini, Giorgia, Bosetti, Tommaso, Callegaro, Annapaola, Di Croce, Andrea, Caremoli, Elena Rota, Moro, Cecilia, Milesi, Laura, Poletti, Paola, Tasca, Cristina, Mandalà, Mario, Merelli, Barbara, Mosconi, Stefania, Arnoldi, Ermenegildo, Bettini, Anna, Bonomi, Lucia, Messina, Caterina, Ghilardi, Laura, Chirco, Alessandra, Maracino, Michela, Tondini, Carlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018331/ https://www.ncbi.nlm.nih.gov/pubmed/33355953 http://dx.doi.org/10.1002/onco.13654 |
Ejemplares similares
-
1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 pandemic in Italy
por: Zambelli, A., et al.
Publicado: (2020) -
A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab
por: Bonomi, Lucia, et al.
Publicado: (2020) -
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
por: Zambelli, Alberto, et al.
Publicado: (2020) -
The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities
por: Klesse, Laura J., et al.
Publicado: (2020) -
Smoking Is Related to Worse Cancer-related Symptom Burden
por: Oswald, Laura B, et al.
Publicado: (2022)